Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study
Descripción general
Resumen del artículo
This observational cohort study suggests that lowering remnant cholesterol, as seen with new APOC3 and ANGPTL3 inhibitors, could reduce 10-year ASCVD risk by 1.4%-4.1%, with greater reductions seen in statin users. However, these are predictions based on observational data and previous genetic studies, assuming a causal link between remnant cholesterol and ASCVD; large randomized controlled trials are needed to confirm these findings.
Explícamelo como si tuviera cinco años
This study suggests that new cholesterol-lowering drugs could significantly reduce heart disease risk, especially in those already taking statins. However, these are predictions based on observations, not clinical trials, so we need real-world testing to confirm.
Posibles conflictos de intereses
Anne Langsted has received honoraria/consultancies from Amarin and Novartis. Anne Langsted and Anette Varbo are employed at Novo Nordisk. Børge G. Nordestgaard reports consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, and Marea.
Limitaciones identificadas
Explicación de la calificación
This is a well-conducted observational study with interesting findings. However, it cannot prove cause-and-effect due to inherent limitations of observational designs. Its reliance on unconfirmed causality between remnant cholesterol and ASCVD and limited generalizability weaken the conclusions. The declared conflicts of interest also impact the rating.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →